Uveitis, Posterior Clinical Trial
Official title:
Open-label, Single-center, Prospective Study on the Efficacy and Safety of Repository Corticotropin Injection (H.P. ACTHAR GEL) in the Treatment of Adults With Non-infectious Retinal Vasculitis
The purpose of this study is to evaluate the short- and long-term efficacy and safety of Acthar for the treatment of adults with non-infectious retinal vasculitis.
Status | Recruiting |
Enrollment | 40 |
Est. completion date | August 2020 |
Est. primary completion date | February 2020 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Any adult patient with active retinal vasculitis (involving arteries or veins) as a manifestation of non-infectious ocular inflammatory disease; fundus must be viewable with wide-field FA in the study eye - If both eyes are involved, both are eligible for inclusion in the study - Patients already on non-steroidal immunosuppressive therapy may continue on this during the study, but the dose must not be increased or decreased within 6 weeks of initiating the trial - Willing and able to sign the informed consent form Exclusion Criteria: - Patients under age 18 - Patients who are pregnant (must be ruled out in women of child-bearing age) - Active infectious ocular or systemic disease - Patients with active infectious ocular or extraocular disease - Patients with history of malignancy, except for dermatologic entities of basal or squamous cell carcinoma which have been completely excised or removed previously - Patients with systemic illness involving abnormalities of the hypothalamic-pituitary-adrenal axis; patients with primary adrenocortical insufficiency or adrenocortical hyperfunction - Patients with known hypersensitivity to Acthar - Patients on other non-steroidal systemic immunomodulatory medications with dose adjusted sooner than 6 weeks prior to study drug administration - Patients currently on or recently treated with (within 6 weeks) systemic corticosteroid - Patients with periocular or intraocular injections of medications administered to help control inflammation sooner than 6 weeks prior to study drug administration - Patients with severe disease that warrants critical attention, deemed unsafe for the study by the investigator, or contraindicated, including but not limited to, patients with scleroderma, osteoporosis, systemic fungal infections, ocular herpes simplex, recent surgery, history of or the presence of a peptic ulcer, congestive heart failure, uncontrolled hypertension, or sensitivity to proteins of porcine origin. Administration of live or live attenuated vaccines is contraindicated in patients during the entire duration of the study and for one month prior |
Country | Name | City | State |
---|---|---|---|
United States | Ocular Immunology & Uveitis Foundation | Waltham | Massachusetts |
Lead Sponsor | Collaborator |
---|---|
Ocular Immunology and Uveitis Foundation |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Percentage of responders to Acthar at the end of treatment. | A responder will be defined by the binominal presence or absence of active retinal vasculitis as evaluated at Week 24. Active retinal vasculitis is defined as angiographic leakage from retinal arterioles, venules, or capillaries as determined by investigator, seen on wide-field angiography. Complete resolution or absence of active retinal vasculitis at Week 24 is considered success or "remission". | 24 Weeks | |
Secondary | Presence or absence of active retinal vasculitis at all other time points. | 1 Day to 24 Weeks | ||
Secondary | Safety assessments, including drug tolerability and adverse events; other ocular and/or systemic complications. | 1 Day to 24 Weeks | ||
Secondary | Percentage of patients requiring rescue therapy. | 1 Day to 24 Weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00570479 -
Prophylactic Anecortave Acetate in Patients With a Retisert Implant
|
Phase 1 | |
Recruiting |
NCT05486468 -
The Use of Two YUTIQ Versus Sham for Treatment of Chronic Non Infectious Intraocular Inflammation Affecting the Posterior Segment
|
Phase 3 | |
Terminated |
NCT03656692 -
Safety and Effectiveness of Acthar Gel for Inflammation of the Eye's Uvea (Middle Layer)
|
Phase 4 | |
Completed |
NCT02255032 -
Suprachoroidal Injection of Triamcinolone Acetonide in Subjects With Macular Edema Following Non-Infectious Uveitis
|
Phase 2 | |
Completed |
NCT00035906 -
Research Study in Patients With Persistent Macular Edema
|
Phase 2 | |
Recruiting |
NCT05101928 -
Ozurdex Monotherapy Trial
|
Phase 4 | |
Terminated |
NCT05070728 -
Safety and Efficacy of an Injectable Fluocinolone Acetonide Intravitreal Insert (FAI)
|
Phase 3 | |
Completed |
NCT02595398 -
Suprachoroidal Injection of CLS-TA in Subjects With Macular Edema Associated With Non-infectious Uveitis
|
Phase 3 | |
Completed |
NCT01539577 -
A Long-Term Safety Study of OZURDEX® in Clinical Practice
|
N/A | |
Recruiting |
NCT05322070 -
Fluocinolone Acetonide Intravitreal Implant 0.18 mg in the Treatment of Chronic Non-Infectious Posterior Segment Uveitis
|
Phase 4 | |
Recruiting |
NCT06085079 -
Ixekizumab for the Management of Refractory Non-Infectious Uveitis: A Proof-of-Concept Study
|
Phase 4 | |
Completed |
NCT03145025 -
Corneal Endothelial Cell Density in Eyes Treated With a Fluocinolone Acetonide Intravitreal Implant
|
||
Withdrawn |
NCT01905124 -
Safety &Efficacy of CF101 to Subjects With Uveitis
|
Phase 2 | |
Completed |
NCT02049476 -
Study of the Effectiveness of Ozurdex for the Control of Uveitis
|
Phase 4 | |
Completed |
NCT03598452 -
High-dose Intravitreal Injection of Ganciclovir for the Treatment of CMVR in HIV-negative Patients
|
N/A | |
Completed |
NCT00404742 -
A Study of LX211 in Clinically Quiescent Non-infectious Intermediate, Anterior and Intermediate, Posterior or Pan-Uveitis
|
Phase 3 | |
Completed |
NCT00404612 -
A Study of LX211 in Active Sight Threatening, Non-infectious Intermediate-, Anterior and Intermediate-, Posterior-, or Pan-Uveitis
|
Phase 3 | |
Completed |
NCT02952001 -
MAGNOLIA: Extension Study of Patients With Non-infectious Uveitis Who Participated in CLS1001-301
|
||
Not yet recruiting |
NCT06431373 -
A Study of Brepocitinib in Adults With Active, Non-Infectious, Non-Anterior Uveitis
|
Phase 3 | |
Completed |
NCT03097315 -
Suprachoroidal Injection of CLS-TA in Patients With Non-infectious Uveitis
|
Phase 3 |